Brian O Mahony/X
Jul 21, 2025, 13:10
What’s Slowing Down Gene Therapy Uptake in Hemophilia? Brian O’Mahony Explains the Real-World Barriers
Brian O’Mahony, CEO of Irish Haemophilia Society,former President of WFH and EHC, highlights several key challenges that are currently limiting the widespread adoption of gene therapy in hemophilia in his recently shared post on X:
“Uncertainty about outcomes and side effects,
Complex reimbursement systems,
Availability of other excellent therapies,
Lack of center preparedness and resources.”
Despite the promise of a functional cure, real-world barriers continue to delay broader implementation.
Want to understand the future of gene therapy and how to overcome systemic obstacles?
Find the latest updates and expert commentary — only on Hemostasis Today, your trusted source for frontline academic insights in hematology and hemostasis.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis